1. Home
  2. NVCR vs LMB Comparison

NVCR vs LMB Comparison

Compare NVCR & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • LMB
  • Stock Information
  • Founded
  • NVCR 2000
  • LMB 1901
  • Country
  • NVCR Switzerland
  • LMB United States
  • Employees
  • NVCR N/A
  • LMB N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • LMB Engineering & Construction
  • Sector
  • NVCR Health Care
  • LMB Consumer Discretionary
  • Exchange
  • NVCR Nasdaq
  • LMB Nasdaq
  • Market Cap
  • NVCR 1.9B
  • LMB 1.6B
  • IPO Year
  • NVCR 2015
  • LMB 2014
  • Fundamental
  • Price
  • NVCR $17.60
  • LMB $148.90
  • Analyst Decision
  • NVCR Buy
  • LMB Strong Buy
  • Analyst Count
  • NVCR 7
  • LMB 3
  • Target Price
  • NVCR $32.43
  • LMB $140.67
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • LMB 183.7K
  • Earning Date
  • NVCR 07-24-2025
  • LMB 08-05-2025
  • Dividend Yield
  • NVCR N/A
  • LMB N/A
  • EPS Growth
  • NVCR N/A
  • LMB 31.50
  • EPS
  • NVCR N/A
  • LMB 2.78
  • Revenue
  • NVCR $621,711,000.00
  • LMB $532,913,000.00
  • Revenue This Year
  • NVCR $5.56
  • LMB $22.19
  • Revenue Next Year
  • NVCR $9.19
  • LMB $8.71
  • P/E Ratio
  • NVCR N/A
  • LMB $53.79
  • Revenue Growth
  • NVCR 18.27
  • LMB 3.62
  • 52 Week Low
  • NVCR $14.17
  • LMB $48.17
  • 52 Week High
  • NVCR $34.13
  • LMB $154.05
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • LMB 62.85
  • Support Level
  • NVCR $16.81
  • LMB $141.92
  • Resistance Level
  • NVCR $18.59
  • LMB $154.05
  • Average True Range (ATR)
  • NVCR 0.74
  • LMB 6.07
  • MACD
  • NVCR 0.08
  • LMB -0.02
  • Stochastic Oscillator
  • NVCR 56.18
  • LMB 75.93

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

Share on Social Networks: